Thrombus

This item requires a subscription.

Orally active antithrombotic agents: a new era in the prevention of VTE
Thrombus, Volume 13, Number 1.

As warfarin was introduced as an oral antithrombotic agent 60 or so years ago, the arrival of new orally active antithrombotic agents represents a significant advance. So far, two agents have been licensed for the prophylaxis of orthopaedic patients undergoing total hip replacement (THR) or total knee replacement (TKR): dabigatran (Pradaxa®, Boehringer Ingelheim, UK) and rivaroxaban, (Xarelto®, Bayer AG, UK). A third drug, apixaban (Pfizer, UK), has completed a Phase III trial, but failed to achieve non-inferiority (NI) in THR patients.

To view this item, select one of the options below:

	Purchase access
	In order to view articles you will need to pay a subscription for either 24-hour or annual access. You can view all articles on this site during the subscription period. Please click here to subscribe.

	Sign in
	If you are already have a subscription, please sign in here.
	email address
	Password
	Forgotten your password?

	Important
	All the articles are in PDF format.
	To view the articles you will need Adobe Acrobat Reader.
	To download a copy, free of charge, please click here.

	Help
	If you need help accessing this site, please click here.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsors, publisher, Editor or Editorial Board. Accordingly the sponsors, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.
Copyright (©) 2010 Hayward Group Ltd. The title Thrombus is the property of Hayward Group Ltd and, together with the content, is bound by copyright. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk